Development of a population-based microsimulation model of osteoarthritis in Canada.

OBJECTIVES The purpose of the study was to develop a population-based simulation model of osteoarthritis (OA) in Canada that can be used to quantify the future health and economic burden of OA under a range of scenarios for changes in the OA risk factors and treatments. In this article we describe the overall structure of the model, sources of data, derivation of key input parameters for the epidemiological component of the model, and preliminary validation studies. DESIGN We used the Population Health Model (POHEM) platform to develop a stochastic continuous-time microsimulation model of physician-diagnosed OA. Incidence rates were calibrated to agree with administrative data for the province of British Columbia, Canada. The effect of obesity on OA incidence and the impact of OA on health-related quality of life (HRQL) were modeled using Canadian national surveys. RESULTS Incidence rates of OA in the model increase approximately linearly with age in both sexes between the ages of 50 and 80 and plateau in the very old. In those aged 50+, the rates are substantially higher in women. At baseline, the prevalence of OA is 11.5%, 13.6% in women and 9.3% in men. The OA hazard ratios for obesity are 2.0 in women and 1.7 in men. The effect of OA diagnosis on HRQL, as measured by the Health Utilities Index Mark 3 (HUI3), is to reduce it by 0.10 in women and 0.14 in men. CONCLUSIONS We describe the development of the first population-based microsimulation model of OA. Strengths of this model include the use of large population databases to derive the key parameters and the application of modern microsimulation technology. Limitations of the model reflect the limitations of administrative and survey data and gaps in the epidemiological and HRQL literature.

[1]  J. Chancellor,et al.  Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland , 2012, PharmacoEconomics.

[2]  G. Bevan,et al.  "Systematic" , 1966, Comput. J..

[3]  J. Chancellor,et al.  An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada , 2012, PharmacoEconomics.

[4]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. , 2008, Osteoarthritis and cartilage.

[5]  C. Helmick,et al.  Projections of US prevalence of arthritis and associated activity limitations. , 2006, Arthritis and rheumatism.

[6]  Richard H. Osborne,et al.  Can we reduce disease burden from osteoarthritis? An evidence-based priority-setting model , 2004 .

[7]  U. Haglund,et al.  The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. , 2000, Rheumatology.

[8]  M. Escobar,et al.  The use of the Tobit model for analyzing measures of health status , 2004, Quality of Life Research.

[9]  J. Kopec,et al.  Impact of chronic conditions. , 2003, Health reports.

[10]  A M Walker,et al.  Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. , 1995, Arthritis and rheumatism.

[11]  K Knahr,et al.  Strategies for the prevention and management of osteoarthritis of the hip and knee. , 2007, Best practice & research. Clinical rheumatology.

[12]  Evaluating the predictive value of osteoarthritis diagnoses in an administrative database. , 2000 .

[13]  A. Brennan,et al.  An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis , 2012, Drugs.

[14]  M L Barer,et al.  Creating a Population-based Linked Health Database: A New Resource for Health Services Research , 1998, Canadian journal of public health = Revue canadienne de sante publique.

[15]  E. Badley,et al.  Revisiting arthritis prevalence projections--it's more than just the aging of the population. , 2006, The Journal of rheumatology.

[16]  J. Berthelot,et al.  Potential impact of population-based colorectal cancer screening in Canada. , 2003, Chronic diseases in Canada.

[17]  J. Berthelot,et al.  Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs , 1999, British Journal of Cancer.

[18]  G. Naglie,et al.  The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[19]  S. Kong,et al.  Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis , 2012, PharmacoEconomics.

[20]  S. Dahrouge,et al.  Lifetime costs of colon and rectal cancer management in Canada. , 2003, Chronic diseases in Canada.

[21]  J. Kopec,et al.  Descriptive epidemiology of osteoarthritis in British Columbia, Canada. , 2007, The Journal of rheumatology.

[22]  E. Feuer,et al.  The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing , 2004, Statistical methods in medical research.

[23]  D. Felson,et al.  Obesity and knee osteoarthritis. The Framingham Study. , 1988, Annals of internal medicine.

[24]  K. Wilkins.  Incident arthritis in relation to excess weight. , 2004, Health reports.

[25]  C. François,et al.  Can discrete event simulation be of use in modelling major depression? , 2006, Cost effectiveness and resource allocation : C/E.

[26]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[27]  Timothy E. McAlindon,et al.  Osteoarthritis: New Insights , 2002 .

[28]  M. Nordin,et al.  Osteoarthritis of the knee and hip and activity: a systematic international review and synthesis (OASIS). , 2006, Joint, bone, spine : revue du rhumatisme.

[29]  H. Morrison,et al.  The burden of adult obesity in Canada. , 2007, Chronic diseases in Canada.

[30]  E. Thomas,et al.  Knee pain and osteoarthritis in the general population: what influences patients to consult? , 2007, Family practice.

[31]  M Egger,et al.  The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.

[32]  J. Berthelot,et al.  BREAST CANCER: BETTER CARE FOR LESS COST , 2000, International Journal of Technology Assessment in Health Care.

[33]  T. Spector,et al.  Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors , 2000, Annals of Internal Medicine.

[34]  J. Berthelot,et al.  Estimates of the lifetime costs of breast cancer treatment in Canada. , 2000, European journal of cancer.

[35]  M. Wolfson,et al.  POHEM--a framework for understanding and modelling the health of human populations. , 1994, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[36]  Milton C. Weinstein,et al.  Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.

[37]  J. Berthelot,et al.  Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions. , 2001, European journal of cancer.

[38]  M. Wolfson,et al.  First do no harm: extending the debate on the provision of preventive tamoxifen , 2001, British Journal of Cancer.

[39]  D. Coyle,et al.  Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[40]  P. Nilsson,et al.  Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study , 2008, Annals of the rheumatic diseases.

[41]  Averill M. Law,et al.  Simulation Modeling and Analysis , 1982 .

[42]  G. Dinant,et al.  Clinical subsequent fractures cluster in time after first fractures , 2008, Annals of the rheumatic diseases.

[43]  J. Perreault,et al.  Population projections for Canada provinces and territories 1989-2011. , 1985 .

[44]  A. Woolf.  The bone and joint decade. strategies to reduce the burden of disease: the Bone and Joint Monitor Project. , 2003, The Journal of rheumatology. Supplement.

[45]  Jacek A Kopec,et al.  Trends in physician-diagnosed osteoarthritis incidence in an administrative database in British Columbia, Canada, 1996-1997 through 2003-2004. , 2008, Arthritis and rheumatism.

[46]  G. Andrews,et al.  Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis. , 2006, The Journal of rheumatology.

[47]  C. Helmick,et al.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. , 1998, Arthritis and rheumatism.

[48]  M Aickin,et al.  The global diabetes model: user friendly version 3.0. , 2000, Diabetes research and clinical practice.

[49]  E. Badley,et al.  Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. , 1998, The Journal of rheumatology.